Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

By sjmartinez • January 7, 2025

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. PMID: 39761965.

Tags: atopic dermatitis, Dermatology, Eczema Area and Severity Index, lebrikizumab, Publications, Quality of Life

BayesAge 2.0: a maximum likelihood algorithm to predict transcriptomic age

Mboning L, Costa EK, Chen J, Bouchard LS, Pellegrini M. BayesAge 2.0: a maximum likelihood algorithm to predict transcriptomic age. Geroscience. 2025 Jan 3. doi:[...]

Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review

Kakani P, Davis J. Racial/Ethnic Disparities in Cutaneous T-cell Lymphoma: A Clinical Review. Skinmed. 2024 Dec 31;22(6):422-426. PMID: 39748573.

An evaluation framework for clinical use of large language models in patient interaction tasks

Johri S, Jeong J, Tran BA, Schlessinger DI, Wongvibulsin S, Barnes LA, Zhou HY, Cai ZR, Van Allen EM, Kim D, Daneshjou R, Rajpurkar P.[...]